Back to MAbs for Pfizer as Dimebon reaches the end of the road in Alzheimer's
This article was originally published in Scrip
Executive Summary
Top-line data show that the once-hyped drug Dimebon (latrepirdine) has again failed to improve Alzheimer's disease symptoms, leading to the discontinuation of all development of the drug. Despite this expected setback, Pfizer can look to the monoclonal antibody bapineuzumab in its Alzheimer's disease pipeline with cautious optimism.